Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

GlaxoSmithKline patent describes novel DGAT1 inhibitors for obesity

June 5, 2014

Health Canada accepts Ravicti NDS for priority review

June 4, 2014

Teriparatide evidences potential for spinal fusion and fractures

June 4, 2014

Merrion Pharmaceuticals' GIPET technology advances with Novo Nordisk oral insulin development

June 3, 2014

Arena Pharmaceuticals and the University of Copenhagen prepare novel GPR119 receptor antagonists

June 3, 2014

Ipsen Pharma synthesizes novel somatostatin receptor agonists

June 3, 2014

Combining GLP-1-expressing plasmids and DPP IV gene silencing for type 2 diabetes

June 3, 2014

Zydus initiates phase III trial of saroglitazar in lipodystrophy

June 2, 2014

Amgen reports results from OSLER study of evolocumab

June 2, 2014

Trimel reports topline phase II results for Tefina

May 30, 2014

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...